Evidence map›Paper›PMID 34937173›Full record

ArticleMicrobiology spectrum2021

Recombinant Fasciola hepatica Fatty Acid Binding Protein as a Novel Anti-Inflammatory Biotherapeutic Drug in an Acute Gram-Negative Nonhuman Primate Sepsis Model.

Jose J Rosado-Franco, Albersy Armina-Rodriguez, Nicole Marzan-Rivera, Armando G Burgos, Natalie Spiliopoulos, Stephanie M Dorta-Estremera, Loyda B Mendez, A M Espino

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Harnessing mRNA technology againstFrontiers in immunology · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jose J Rosado-FrancoDepartment of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campusgrid.267034.4, San Juan, Puerto Rico.
Albersy Armina-RodriguezDepartment of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campusgrid.267034.4, San Juan, Puerto Rico.
Nicole Marzan-RiveraDepartment of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campusgrid.267034.4, San Juan, Puerto Rico.
Armando G BurgosCaribbean Primate Research Center University of Puerto Rico, Medical Sciences Campusgrid.267034.4, Toa Baja, Puerto Rico.
Natalie SpiliopoulosCaribbean Primate Research Center University of Puerto Rico, Medical Sciences Campusgrid.267034.4, Toa Baja, Puerto Rico.
Stephanie M Dorta-EstremeraDepartment of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campusgrid.267034.4, San Juan, Puerto Rico.
Loyda B MendezDepartment of Science & Technology, Universidad Ana G. Mendez, Recinto de Carolina, Carolina, Puerto Rico.
A M EspinoDepartment of Microbiology and Medical Zoology, University of Puerto Rico, Medical Sciences Campusgrid.267034.4, San Juan, Puerto Rico.ORCID 0000-0001-8456-2550
University of Puerto Rico, Medical Sciences Campus · PRAna G. Mendez University System · PR

Funding

Translational Science InitiativeP40OD012217 · OD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CARLOS A SARIOL · 2012 to 2026
$40.4M
Upgrade Laboratories Facilities at UPR-Rio PiedrasR25GM061151 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2001 to 2023
$32.5M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
TRANSLATIONAL PROTEOMICS CENTERG12MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FERNANDEZ-REPOLLET, EMMA · 2012 to 2016
$11.0M
Targeting professional APCs using Fasciola hepatica FABP to suppresses inflammationSC1AI155439 · NIAID · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI ESPINO, ANA M · 2020 to 2023
$1.5M
HHS | NIH | Office of Research Infrastructure Programs, National Institutes of Health (ORIP) P40OD12271NIAID NIH HHS SC1 AI155439NIGMS NIH HHS R25 GM061151NIGMS NIH HHS R25 GM061838NIH HHS P40 OD012217NIMHD NIH HHS G12 MD007600
6 · The paper itself

Abstract

Due to their phylogenetic proximity to humans, nonhuman primates (NHPs) are considered an adequate choice for a basic and preclinical model of sepsis. Gram-negative bacteria are the primary causative of sepsis. During infection, bacteria continuously release the potent toxin lipopolysaccharide (LPS) into the bloodstream, which triggers an uncontrolled systemic inflammatory response leading to death. Our previous research has demonstrated

Indexed as

AnimalsAnti-Inflammatory AgentsBacteremiaCytokinesDisease Models, AnimalFasciola hepaticaFatty Acid-Binding ProteinsGram-Negative BacteriaHelminth ProteinsHumansMacaca mulattaMaleRecombinant ProteinsToll-Like Receptor 4Anti-Inflammatory AgentsCytokinesFatty Acid-Binding ProteinsHelminth ProteinsRecombinant ProteinsToll-Like Receptor 4cytokinesFasciola hepaticafatty acid binding proteinrhesus macaquessepsis

Identifiers

PMID34937173
PMCPMC8694124
OpenAlexW4200114471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.